Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
10
×
drugs
10
×
life sciences
national blog main
clinical trials
fda
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
boston
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
patisiran
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alnylam pharmaceuticals
cancer
inotersen
onpattro
pfizer
tafamidis
deals
What
fda
10
×
drug
medicine
alnylam
approved
new
ago
oks
rna
approval
bio
companies
decades
disease
drugs
genetic
interference
make
patients
rnai
roundup
second
time
uses
year
ahead
akcea
aldeyra
amyloidosis
approve
approves
arguments
asco
attr
available
awaits
battle
big
biological
branded
Language
Current search:
drugs
×
fda
×
" boston top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision